Format
Items per page
Sort by

Send to:

Choose Destination

Search results

Items: 1 to 20 of 181

1.

Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer-A retrospective analysis of kinetics on 743 breast cancer patients.

Stieber P, Nagel D, Blankenburg I, Heinemann V, Untch M, Bauerfeind I, Di Gioia D.

Clin Chim Acta. 2015 Aug 25;448:228-31. doi: 10.1016/j.cca.2015.06.022. Epub 2015 Jul 6.

PMID:
26160053
2.

Preoperative serum markers for individual patient prognosis in stage I-III colon cancer.

Giessen-Jung C, Nagel D, Glas M, Spelsberg F, Lau-Werner U, Modest DP, Schulz C, Heinemann V, Di Gioia D, Stieber P.

Tumour Biol. 2015 Sep;36(10):7897-906. doi: 10.1007/s13277-015-3522-z. Epub 2015 May 8.

PMID:
25953265
3.

Early detection of metastatic disease in asymptomatic breast cancer patients with whole-body imaging and defined tumour marker increase.

Di Gioia D, Stieber P, Schmidt GP, Nagel D, Heinemann V, Baur-Melnyk A.

Br J Cancer. 2015 Mar 3;112(5):809-18. doi: 10.1038/bjc.2015.8. Epub 2015 Feb 3.

PMID:
25647014
4.

Serum HER2 in combination with CA 15-3 as a parameter for prognosis in patients with early breast cancer.

Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Stieber P.

Clin Chim Acta. 2015 Feb 2;440:16-22. doi: 10.1016/j.cca.2014.11.001. Epub 2014 Nov 7.

PMID:
25444743
5.

Evaluation of preoperative serum markers for individual patient prognosis in stage I-III rectal cancer.

Giessen C, Nagel D, Glas M, Spelsberg F, Lau-Werner U, Modest DP, Michl M, Heinemann V, Stieber P, Schulz C.

Tumour Biol. 2014 Oct;35(10):10237-48. doi: 10.1007/s13277-014-2338-6. Epub 2014 Jul 17.

PMID:
25027407
6.

Circulating cell-free methylated DNA and lactate dehydrogenase release in colorectal cancer.

Philipp AB, Nagel D, Stieber P, Lamerz R, Thalhammer I, Herbst A, Kolligs FT.

BMC Cancer. 2014 Apr 8;14:245. doi: 10.1186/1471-2407-14-245.

7.

Serum HER2 supports HER2-testing in tissue at the time of primary diagnosis of breast cancer.

Di Gioia D, Dresse M, Mayr D, Nagel D, Heinemann V, Kahlert S, Stieber P.

Clin Chim Acta. 2014 Mar 20;430:86-91. doi: 10.1016/j.cca.2013.12.036. Epub 2014 Jan 9.

PMID:
24412321
8.

Circulating nucleosomes and immunogenic cell death markers HMGB1, sRAGE and DNAse in patients with advanced pancreatic cancer undergoing chemotherapy.

Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D, Holdenrieder S.

Int J Cancer. 2013 Dec 1;133(11):2619-30. doi: 10.1002/ijc.28294. Epub 2013 Aug 9.

9.

Cytokeratin 19-fragments (CYFRA 21-1) as a novel serum biomarker for response and survival in patients with advanced pancreatic cancer.

Boeck S, Wittwer C, Heinemann V, Haas M, Kern C, Stieber P, Nagel D, Holdenrieder S.

Br J Cancer. 2013 Apr 30;108(8):1684-94. doi: 10.1038/bjc.2013.158. Epub 2013 Apr 11.

10.

Magnetic resonance colonography for the detection of colorectal neoplasia in asymptomatic adults.

Graser A, Melzer A, Lindner E, Nagel D, Herrmann K, Stieber P, Schirra J, Mansmann U, Reiser MF, Göke B, Kolligs FT.

Gastroenterology. 2013 Apr;144(4):743-750.e2. doi: 10.1053/j.gastro.2012.12.041. Epub 2013 Feb 13.

PMID:
23415805
11.

DNase is a prognostic marker in liver cancer patients receiving transarterial chemoembolization therapy.

Kohles N, Nagel D, Jüngst D, Stieber P, Holdenrieder S.

Int J Clin Pharmacol Ther. 2013 Jan;51(1):80-3. No abstract available.

12.

Soluble receptor of advanced glycation end products (sRAGE) indicates response to chemotherapy in pancreatic cancer patients.

Wittwer C, Boeck S, Heinemann V, Haas M, Stieber P, Nagel D, Holdenrieder S.

Int J Clin Pharmacol Ther. 2013 Jan;51(1):67-9. No abstract available.

13.

CA 15-3 is a predictive and prognostic biomarker in patients with metastasized breast cancer undergoing Selective Internal Radiation Therapy.

Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P, Holdenrieder S.

Int J Clin Pharmacol Ther. 2013 Jan;51(1):63-6. No abstract available.

14.

Human epididymis protein 4 (HE4) in benign and malignant diseases.

Hertlein L, Stieber P, Kirschenhofer A, Krocker K, Nagel D, Lenhard M, Burges A.

Clin Chem Lab Med. 2012 Dec;50(12):2181-8.

PMID:
23093276
15.

Prognosis of patients with hepatocellular carcinoma. Validation and ranking of established staging-systems in a large western HCC-cohort.

op den Winkel M, Nagel D, Sappl J, op den Winkel P, Lamerz R, Zech CJ, Straub G, Nickel T, Rentsch M, Stieber P, Göke B, Kolligs FT.

PLoS One. 2012;7(10):e45066. doi: 10.1371/journal.pone.0045066. Epub 2012 Oct 5.

16.

Immunogenic cell death biomarkers HMGB1, RAGE, and DNAse indicate response to radioembolization therapy and prognosis in colorectal cancer patients.

Fahmueller YN, Nagel D, Hoffmann RT, Tatsch K, Jakobs T, Stieber P, Holdenrieder S.

Int J Cancer. 2013 May 15;132(10):2349-58. doi: 10.1002/ijc.27894. Epub 2013 Jan 18.

17.

Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy.

Kohles N, Nagel D, Jüngst D, Stieber P, Holdenrieder S.

Tumour Biol. 2012 Dec;33(6):2401-9. doi: 10.1007/s13277-012-0504-2. Epub 2012 Sep 11.

PMID:
22965881
18.

Anthracycline-induced cardiotoxicity: cardiac monitoring by continuous wave-Doppler ultrasound cardiac output monitoring and correlation to echocardiography.

Geiger S, Stemmler HJ, Suhl P, Stieber P, Lange V, Baur D, Hausmann A, Tischer J, Horster S.

Onkologie. 2012;35(5):241-6. doi: 10.1159/000338335. Epub 2012 Apr 23.

PMID:
22868502
19.

Nature and dynamics of nucleosome release from neoplastic and non-neoplastic cells.

Holdenrieder S, Kolligs FT, Braess J, Manukyan D, Stieber P.

Anticancer Res. 2012 May;32(5):2179-83.

PMID:
22593507
20.

Cytokeratin serum biomarkers in patients with colorectal cancer.

Holdenrieder S, Stieber P, Liska V, Treska V, Topolcan O, Dreslerova J, Matejka VM, Finek J, Holubec L.

Anticancer Res. 2012 May;32(5):1971-6.

PMID:
22593474
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk